-

Perspectum Announces American Medical Association Issues Unique Category III CPT® Codes for LiverMultiScan® Quantitative Multiparametric MR

SAN FRANCISCO--(BUSINESS WIRE)--The American Medical Association (AMA) has issued two new Current Procedural Terminology (CPT®) codes for Quantitative Multiparametric MR to report LiverMultiScan, which can help clinicians diagnose and treat patients with liver disease.

LiverMultiScan is the most comprehensive liver MR exam that measures liver fat, iron, fibrosis, and inflammation. The technology was developed by Perspectum, leaders in innovative imaging solutions for patients with metabolic disease. LiverMultiScan is designed to help clinicians care for patients with fatty liver disease such as non-alcoholic steatohepatitis (NASH). These patients typically undergo blood tests then an invasive biopsy procedure. LiverMultiScan reduces the need for liver biopsy and provides the care team with a quantitative report to help monitor therapy.

The newly won CPT codes were submitted collectively by the American College of Radiology, Radiological Society of North America, American Roentgen Ray Society, and Association of University Radiologists. This code submission is a testament to how industry and medical societies can successfully collaborate to advance patient access to innovative technologies.

CPT codes are granted and regulated by the AMA CPT Editorial Panel and are widely used by government payers, including Medicare and Medicaid, and commercial health plans to describe healthcare services and procedures for reimbursement. The release of these new codes represents a major reimbursement milestone as hospitals and imaging centers across the US will be able to submit claims directly related to the service. Ultimately, these new codes will provide millions of patients with access to LiverMultiScan for the care and management of liver disease.

Emir Sandhu, MD, Vice President at the Blue Venture Fund comments "The AMA's issuance of two CPT codes for LiverMultiScan is a significant milestone in the path to providing patients with more precise diagnostics and better management of liver disease. LiverMultiScan is uniquely positioned to help curb the staggering morbidity and mortality associated with Nonalcoholic Fatty Liver Disease."

The new LiverMultiScan Quantitative Multiparametric MR Category III CPT codes will become effective on July 1st, 2021. They include:

0648T -- Quantitative magnetic resonance for analysis of tissue composition (e.g., fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the same anatomy (e.g., organ, gland, tissue, target structure) during the same session.

0649T -- Quantitative magnetic resonance for analysis of tissue composition (e.g., fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (e.g., organ, gland, tissue, target structure) (List separately in addition to code for primary procedure).

Notes to editors:

About Perspectum

Perspectum delivers cutting-edge digital technologies that help clinicians provide better care for patients with liver disease, diabetes, and cancer. With a strong focus on precision medicine using advanced medical imaging and genetics, our vision is to empower patients and clinicians through quantitative assessments of health enabling early detection, diagnosis, and targeted treatment. With a diverse team of physicians, biomedical scientists, engineers, and technologists, Perspectum offers a way to manage complex health problems at scale. For more information, visit www.perspectum.com.

Contacts

Media Contact
Jasmin Hounsell, Head of Marketing
469.390.2122
Jasmin.Hounsell@perspectum.com

Perspectum

Details
Headquarters: Oxford, United Kingdom
CEO: Rajarshi Banerjee
Employees: 250
Organization: PRI

Release Summary
Two new CPT® codes have been issued by the AMA for LiverMultiScan, which can help clinicians diagnose and treat patients with liver disease.
Release Versions

Contacts

Media Contact
Jasmin Hounsell, Head of Marketing
469.390.2122
Jasmin.Hounsell@perspectum.com

More News From Perspectum

Perspectum and InHealth Announce National Diagnostics Partnership to Boost Oxford CDC Capacity and Widen Access to Advanced MRI Across the UK

OXFORD, England--(BUSINESS WIRE)--Perspectum and InHealth announce national diagnostics partnership to boost Oxford CDC capacity and widen access to advanced MRI across the UK....

New Analysis Shows Corrected T1 (cT1) Is the Most Appropriate Diagnosis and Monitoring Tool for Widespread Adoption of Resmetirom Treatment in the United States

WASHINGTON--(BUSINESS WIRE)--Economic analysis shows LiverMultiScan is the most appropriate diagnosis and monitoring tool for scalable adoption of resmetirom in the United States....

Major Study Shows Liver Health Measured with cT1 Predicts Clinical Outcomes

WASHINGTON--(BUSINESS WIRE)--Liver disease is a modifiable cardiac risk factor, and this study confirmed that it can be quantified with MRI iron corrected T1 or cT1....
Back to Newsroom